SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 224 filers reported holding SAGE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,737,843 | +96.1% | 181,625 | +348.1% | 0.47% | +80.2% |
| Q2 2023 | $1,905,768 | +72.6% | 40,531 | +54.0% | 0.26% | +74.7% |
| Q1 2023 | $1,104,387 | +195.1% | 26,320 | +168.3% | 0.15% | +145.9% |
| Q4 2022 | $374,192 | -1.0% | 9,811 | +1.6% | 0.06% | +7.0% |
| Q3 2022 | $378,000 | -86.3% | 9,659 | -88.7% | 0.06% | -76.5% |
| Q2 2022 | $2,751,000 | -27.5% | 85,161 | -25.7% | 0.24% | -25.7% |
| Q1 2022 | $3,794,000 | +14.8% | 114,616 | +47.5% | 0.33% | +29.8% |
| Q4 2021 | $3,305,000 | -16.1% | 77,683 | -12.6% | 0.25% | -11.0% |
| Q3 2021 | $3,939,000 | -24.8% | 88,900 | -3.6% | 0.28% | -18.2% |
| Q2 2021 | $5,238,000 | +53.8% | 92,209 | +102.6% | 0.35% | +41.2% |
| Q1 2021 | $3,406,000 | -45.9% | 45,503 | -37.5% | 0.24% | -42.5% |
| Q4 2020 | $6,298,000 | +31.2% | 72,800 | -7.3% | 0.43% | +34.4% |
| Q3 2020 | $4,802,000 | +6.3% | 78,570 | -27.7% | 0.32% | +3.3% |
| Q2 2020 | $4,519,000 | – | 108,675 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |